Why Is Diversity Important In Clinical Trials
Researchers need participants who represent all types of races and ethnicities, genders, geographic locations, and sexual orientations.
When research involves a group of people who are similar, the findings may not apply to or benefit everyone. When clinical trials include diverse participants, the study results may have a much wider applicability.
Having diverse people in studies can help researchers understand how dementia affects certain groups, why some communities are disproportionately affected by certain dementias, and which treatments or prevention strategies may be most effective in particular groups.
Advancing Understanding Of Transportation Options
Sorry, in progress, not accepting new patients
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers. This multi-site trial will test the driving decision aid in improving decision making and quality and determine its effects on specific subpopulations of older drivers . The overarching hypotheses are that the DDA will help older adults make high-quality decisions, which will mitigate the negative psychosocial impacts of driving reduction, and that optimal DDA use will target certain populations and settings.
La Jolla, California and other locations
Characterizing Cognitive Decline In Late Life Depression: The Adni Depression Project
Sorry, in progress, not accepting new patients
The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression . This is a non-randomized, observational, non-treatment study. One hundred and twenty subjects who meet criteria for Major Depression or LLD will be enrolled for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison. Depression history, symptom severity and health information will be collected at the initial psychiatric visit to determine eligibility. A 3 Tesla Magnetic resonance imaging scan and florbetapir amyloid imaging will be conducted at the ADNI clinic site visits. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.
at UCSF
Recommended Reading: How To Help Someone With Parkinson’s Dementia
University Of California San Diego
Alias:ADRC, UCSD, UC San Diego
- Address9444 Medical Center DrSuite 1-100
- Application Process:Call for more information
- Eligibility Requirements:Eligibility criteria varies depending on the type of research. Call for information and screening.. Call for details/more information. Bring medical records for research eligibility
- Acronym:ADRC, UCSD, UC San Diego
- Payment/Insurance Accepted:Please contact provider for accepted forms of payment.
Tell us about the person you’re helping:
All comments are subject to review. If it’s decided that a comment is inappropriate then it will be deleted from the site.
A Research Study Investigating Semaglutide In People With Early Alzheimer’s Disease
Sorry, not currently recruiting here
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer’s disease. Participants will either get semaglutide or placebo – which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks . Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
at UCLA
Recommended Reading: Is Dementia A Psychiatric Or Neurological Disorder
Assistant Clinical Research Coordinator
Extended Review Date: Wed 12/28/2022Apply NowUC San Diego values equity, diversity, and inclusion. If you are interested in being part of our team, possess the needed licensure and certifications, and feel that you have most of the qualifications and/or transferable skills for a job opening, we strongly encourage you to apply.For the safety and well-being of the entire university community, the University of California requires, with few exceptions, that all students, faculty and staff be vaccinated against the COVID-19 virus and influenza before they will be allowed on campus or in a facility or office. For more information visit: Flu Vaccine Mandate / COVID Vaccine Policy
UCSD Layoff from Career Appointment: Apply by 12/14/2022 for consideration with preference for rehire. All layoff applicants should contact their Employment Advisor.
Special Selection Applicants: Apply by 12/27/2022. Eligible Special Selection clients should contact their Disability Counselor for assistance.
Placement within the salary range is determined by internal equity, relevant qualifications, and collective bargaining agreements .
Alzheimer’s Disease Neuroimaging Initiative 3 Protocol
open to eligible people ages 55-90
Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease . The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
La Jolla, California
Don’t Miss: Can A Person With Dementia Sign A Legal Document
Section : Early Stage Clinical Drug Development
| Natalie Denburg, University of Iowa | Melatonin, a hormone that regulates sleep, to improve cognition in older adults | Older adults | 2024 |
| Barry Greenberg, Johns Hopkins University | Trazadone, an antidepressant to treat sleep disturbance and improve cognitive outcomes | Individuals with prodromal AD/amnestic Mild Cognitive Impairment and sleep complaints | 2026 |
| Population | Anticipated Completion Date | |||
|---|---|---|---|---|
| Nicotinamide riboside , an orally bioavailable precursor of NAD+, to enhance mitochondrial function, and improve cognition | Adults with mild cognitive impairment and mild Alzheimers disease | 2025 | ||
| T3D-959, a small molecule PPAR and PPAR agonist to improve cognition in AD | Adults with mild to severe Alzheimer’s disease | 2023 | ||
| Gary Gibson, Winifred Masterson Burke Medical Research Institute | Benfotiamine, a small molecule thiamine derivative to improve cognition and overall global function | Inidividuals with early AD, including mild cognitive impairment and mild dementia with plasma evidence of amyloid positivity | 2027 | |
| NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults with Mild Cognitive Impairment |
Christopher Martens, University of Colorado |
Nicotinamide Riboside, a precursor molecule of Nicotinamide adenine dinucleotide to improve cerebrovascular function and improve memory in patients with MCI | People with amnestic mild cognitive impairment | 2023 |
Welcome From Dr Brewer
Thank you for your commitment to our groundbreaking programs at the Shiley-Marcos Alzheimers Disease Research Center. With the goal of eradicating Alzheimers disease and related disorders, we have been agile in developing new ways to advance our mission and share the impacts of our research. We are determined to sustain and enhance meaningful engagement throughout our diverse communities. In collaboration with local and national partners, we are forging ahead on transformative paths of discovery that will hasten our understanding of the disease, and we are developing new processes to deliver this understanding toward new therapeutics. I invite you to join us in our endeavors, and I thank you for your partnership. James Brewer, M.D., Ph.D., Director
Don’t Miss: How To Deal With Alzheimer’s Denial
A Study Of Potential Disease Modifying Treatments In Individuals At Risk For Or With A Type Of Early Onset Ad Caused By A Genetic Mutation
Sorry, not currently recruiting here
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer’s disease -causing mutation. Part 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta pathological disease accumulation demonstrated by Aβ positron emission tomography imaging. Part 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
La Jolla, California and other locations
Is Obstructive Sleep Apnea Important In The Development Of Alzheimer’s Disease
open to eligible people ages 65-85
Obstructive sleep apnea is common in older adults and has recently been implicated in pathogenesis of Alzheimer’s disease . Research has shown that sleep disruptions have caused memory impairment. Sleep apnea is a form of sleep disruption. We would like to examine how obstructive sleep apnea may contribute to the progression of Alzheimer’s disease.
La Jolla, California
Don’t Miss: Purple Ribbon For Alzheimer’s
The Kronos Early Estrogen Prevention Study
Sorry, in progress, not accepting new patients
To assess effects of menopausal hormone therapy and normal aging on cognitive performance and imaging markers of brain structure in women approximately thirteen years after enrolling in the KEEPS trial. KEEPS participants were randomized to oral or transdermal estrogen treatments or placebo within three years of menopause. This is a follow up study of these women approximately thirteen years after randomization No treatments are given as part of this study any current hormonal treatments are by choice and prescribed by the participant’s personal physician.
at UCSF
Phenotype Genotype & Biomarkers In Als And Related Disorders
Sorry, accepting new patients by invitation only
The goals of this study are: to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis and related diseases, including primary lateral sclerosis , hereditary spastic paraplegia , progressive muscular atrophy , and frontotemporal dementia and to develop biomarkers that might be useful in aiding therapy development for this group of disorders.
San Diego, California and other locations
You May Like: How Do You Calm Down Someone With Alzheimer’s
Details From The Alzheimers Drug Clinical Trial
The recent clinical trial was conducted at 235 sites in North America, Asia, and Europe between March 2019 and March 2021. The study involved nearly 1,800 adults ages 50 to 90. All the participants had some form of early dementia or Alzheimers disease. Half of the participants were given lecanemab and the other half were given a placebo.
Researchers reported there wasnt a significant difference between lecanemab and the placebo at 12 months, but at 18 months it appeared the people taking lecanemab had some clearance of amyloid and less cognitive decline.
However, researchers said participants taking lecanemab had a higher percentage of adverse events than people taking the placebo at both 12 months and 18 months.
Nonetheless, officials at Biogen and Eisai, the developers of lecanemab, said the latest clinical trial provided hope for the Alzheimers community.
Todays announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimers disease and provide a clinically meaningful impact on cognition and function, said Michel Vounatsos, the chief executive officer at Biogen, in a statement. Importantly, the study shows that removal of aggregated amyloid beta in the brain is associated with a slowing of disease in patients at the early stage of the disease.
An Electronic Clinical Decision Support Tool To Reduce Low
Sorry, accepting new patients by invitation only
The goal of this study will be to design, implement and test the impact of a quality improvement intervention that uses an EHR CDS tool among physicians newly ordering an antipsychotic medication for older adults with ADRD. The study team hypothesizes that the intervention will reduce each participating clinician’s pill days per patient prescribed.
at UCLA
Also Check: What Are The Four Most Common Forms Of Dementia
Napping Sleep Cognitive Decline And Risk Of Alzheimer’s Disease
open to eligible people ages 65 years and up
This study aimed to pilot test a non-pharmacological treatment program targeting improved cognition through improving 24-h sleep-wake cycle in people with mild cognitive impairment or mild Alzheimer’s disease. A treatment program incorporating bright light therapy and a modified cognitive behavioral therapy for insomnia will be developed to address 24-hour patterns of sleep. We will then pilot test its feasibility and explore its preliminary effects on improving sleep/napping and cognition in patients with MCI or mild Alzheimer’s disease.
at UCSF
Clinical Trials Ontario To Make Ontario A Preferred Location For Global Clinical Trials
TORONTO, July 5, 2012 /PRNewswire/ – Clinical Trials Ontario officially launched at the 2012 BIO International Convention, the global event for biotechnology. The pharmaceutical industry welcomed the announcement as a boost to drug development in Ontario.
Clinical Trials Ontario has been created as a province-wide entity to make Ontario the preferred location for global clinical trials activity while maintaining the highest ethical standards.
While Clinical Trials Ontario’s goal is to comprehensively make Ontario more competitive in the global clinical trials marketplace, its initial strategic approach is to streamline the ethics review and contract approval processes for industry-driven multi-site clinical trials inOntario.
Creating Clinical Trials Ontario satisfies one of the strategic initiatives under the government’s Life Sciences Commercialization Strategy to help position Ontario as one of the world’s leading life sciences jurisdictions. This will ensure cutting-edge healthcare discoveries and products are developed and nurtured in Ontario keeping and creating high-value jobs in Ontario and providing Ontarians with early access to innovative approaches to health care through investigational drugs, devices and services.
This approach will also reduce duplication, shorten study start-up time, provide the highest quality of review and ensure the highest standard of patient safety while increasing patient access to investigational therapies.
QUOTES
QUICK FACTS
You May Like: Retinal Scan For Alzheimer’s
A Research Priority And A Familys Heartbreak
Alzheimers Disease is a progressive neurological disorder affecting millions of Americans, most of whom are not yet diagnosed. It slowly destroys memory and thinking skills, leaving the patient unable to manage basic daily tasks without considerable support. It is the sixth leading cause of death in the United States, but the National Institute on Aging said current estimates suggest it might actually be third after heart disease and cancer.
The chances of developing AD are not equal and are quite complicated. Older age does not cause AD, but advancing age, specifically for late-onset disease, is the most common form. Early-onset AD occurs in less than 10 percent of cases, typically between ages 30 to mid-60s. It is often linked to an inherited change in one of three genes. AD can run in families, though a family history is not necessary to develop the disease.
Other AD risk factors are modifiable. Smoking, poor diet, high blood pressure and low physical activity have all been associated with a heightened risk. Some populations and demographics are hit harder than others, though existing research and data is far from comprehensive and equitable.
The complexity of AD has long stymied a full understanding of the condition, not to mention discovery of any preventive or curative remedies, but scientists remain undaunted. Too muchand too many peopleremain at risk.
Collaborative Efforts
Mending Genes
Repurposed Drugs
Finding a Cure
Reaction From Alzheimers Organizations To Lecanemab Approval
The FDAs approval of lecanemab was met with praise from officials at several Alzheimers organizations.
The Alzheimers Association welcomes and celebrates this action by the FDA. We now have a second approved treatment that changes the course of Alzheimers disease in a meaningful way for people in the early stages of the disease, said Joanne Pike, DrPH, the president and chief executive officer of the Alzheimers Association.
By slowing progression of the disease when taken in the early stages of Alzheimers, individuals will have more time to participate in daily life and live independently, she added. This could mean more months of recognizing their spouse, children, and grandchildren. This could also mean more time for a person to drive safely, accurately and promptly take care of family finances, and participate fully in hobbies and interests.
The reaction was equally positive from the Alzheimers Drug Discovery Foundation .
Todays news is incredibly important and a source of optimism not only for patients but also for the medical and research community, said Dr. Howard Fillit, the co-founder and chief science officer of the ADDF, in a press statement. It shows us that our years of research into what is arguably the most complex disease humans face is paying off and it gives us hope that we can make Alzheimers not just treatable, but preventable.
However, Fillit also issued a caution.
Pike added that insurance coverage will also be an important hurdle.
You May Like: How Can You Tell If Someone Has Alzheimer’s Or Dementia
Salsalate In Patients Mild To Moderate Alzheimer’s Disease
Sorry, in progress, not accepting new patients
The purpose of the study is to test the safety and tolerability of twice daily Salsalate in patients with mild to moderate Alzheimer’s Disease. Half of the participants will receive Salsalate and half will receive placebo during the 1-year duration of the study.
San Diego, California
A Trial To Evaluate The Efficacy And Safety Of Pq912 In Patients With Early Ad
open to eligible people ages 50-89
This is a phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to phase 2B. In phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants. In the event that the stage gate for phase 2B is reached, then phase 2B will assesses efficacy and longer-term safety in a larger study group, i.e., 414.
La Jolla, California
Also Check: Gloves For Alzheimer’s Patients